{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:51:34Z","timestamp":1761540694965,"version":"build-2065373602"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2137,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p>A 62\u2010year\u2010old man with a history of coronary artery disease and coronary artery bypass graft, chronic heart failure, and peripheral vascular disease required percutaneous coronary intervention (PCI) after progression of shortness of breath and fatigue over 2 years. Four hours after the procedure, the patient developed hematemesis and was found to be thrombocytopenic. The thrombocytopenia was presumed to be due to the abciximab infusion the patient received during and shortly after the PCI. Further review of the patient's medical history revealed that a similar episode had occurred 11 years earlier. At that time, he was enrolled in a clinical trial comparing tirofiban and heparin in patients with unstable angina; he developed profound thrombocytopenia within 24 hours of randomization. After the study unblinding, investigators discovered that the patient received tirofiban, which was thought to be the cause of his thrombocytopenia. Both abciximab and tirofiban are glycoprotein IIb\u2010IIIa inhibitors, and thrombocytopenia induced by this class of drugs is a serious and potentially life\u2010threatening adverse reaction. The mechanism is not well understood but has been described as immune mediated with both ligand\u2010mimetic agents (tirofiban and eptifibatide) and abciximab. Our patient's situation was unusual in that he developed thrombocytopenia from a ligand\u2010mimetic agent and subsequently had a similar reaction to abciximab. To our knowledge, this case report is the first documentation of thrombocytopenia associated with both tirofiban and abciximab in a single patient, and suggests that care should be given in administering glycoprotein IIb\u2010IIIa inhibitors of either type to patients with a history of thrombocytopenia due to one of these agents.<\/jats:p>","DOI":"10.1592\/phco.26.3.423","type":"journal-article","created":{"date-parts":[[2006,2,27]],"date-time":"2006-02-27T08:49:56Z","timestamp":1141030196000},"page":"423-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Abciximab\u2010Associated Thrombocytopenia After Previous Tirofiban\u2010Related Thrombocytopenia"],"prefix":"10.1002","volume":"26","author":[{"given":"Michael P.","family":"Dorsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Montague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo E.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cam","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1445"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.12.051"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427150-00007"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.2_suppl.53S"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2071"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2054"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.4.809"},{"key":"e_1_2_1_12_2","first-page":"109","article-title":"Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab\u2010associated thrombocytopenia 10 months earlier","volume":"12","author":"Desai M.","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_13_2","first-page":"471","article-title":"Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab\u2010associated acute profound thrombocytopenia","volume":"13","author":"Rao J.","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.292.34883"},{"key":"e_1_2_1_15_2","unstructured":"National Institutes of Health.Platelet transfusion therapy. NIH consensus statement online October 6\u20138 1986. Available fromhttp:www.consensus.nih.gov. Accessed May 23 2005."},{"key":"e_1_2_1_16_2","first-page":"56","article-title":"Acute profound thrombocytopenia without bleeding complications after readministration","volume":"13","author":"Nguyen N.","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0002-9149(96)00582-6","article-title":"Abciximab\u2010associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusions","volume":"78","author":"Kereiakes D.J.","year":"1996","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050272"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.3.423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.3.423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:25:24Z","timestamp":1761067524000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.3.423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1592\/phco.26.3.423"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.3.423","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}